Purple Biotech stock analysis
Purple Biotech (1YI0) Stock Price & Analysis
1YI0 Stock Chart & Stats
- Day’s Range
- EUR 0.28 - EUR 0.38
- 52-Week Range
- EUR 0.28 - EUR 0.38
- Previous Close
- EUR 0.28
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 9.06M
- Enterprise Value
- -EUR 4.20M
- Total Cash (Recent Filing)
- EUR 6.11M
- Total Debt (Recent Filing)
- EUR 134.00K
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage reduces refinancing and solvency pressure while preserving financial flexibility for clinical development. Although the company is loss-making, its limited debt burden avoids adding substantial interest obligations or mandatory repayment demands during the commercialization process.
Strengthening Oncology IP
The CAPTN-3 patent allowance strengthens protection for Purple Biotech’s modular multispecific antibody platform and may improve its ability to pursue development partnerships. Durable intellectual-property coverage can support pipeline differentiation and preserve strategic options as oncology assets advance.
Experienced Leadership Continuity
Returning an experienced former chief executive provides operational continuity during the search for permanent leadership. His prior company knowledge and healthcare background may help maintain strategic focus, while the former CEO’s continued corporate-development role preserves institutional expertise and partnering attention.
Bears Say
No Meaningful Revenue
The absence of meaningful revenue confirms that Purple Biotech remains pre-commercial and lacks a recurring operating base to fund research internally. Until an asset reaches commercialization or a partnership generates material income, financial performance will remain highly dependent on pipeline progress and external capital.
Persistent Large Losses
Persistent sizable losses show that research and development spending has not yet produced a stable commercial offset. Continued negative earnings can accelerate shareholder-capital consumption, constrain strategic flexibility, and make future performance increasingly dependent on successful clinical and partnering outcomes.
Ongoing Cash Burn And Capital Erosion
Negative operating and free cash flow indicate that the business is not self-funding, while the shrinking equity base reflects the cumulative effect of losses and possible dilution. This creates ongoing dependence on external funding and can limit the company’s ability to advance programs without financing risk.
1YI0 FAQ
What was Purple Biotech’s price range in the past 12 months?
What is Purple Biotech’s market cap?
When is Purple Biotech’s upcoming earnings report date?
How were Purple Biotech’s earnings last quarter?
Is Purple Biotech overvalued?
Does Purple Biotech pay dividends?
What is Purple Biotech’s EPS estimate?
How many shares outstanding does Purple Biotech have?
What happened to Purple Biotech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Purple Biotech?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Purple Biotech
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Isaac Israel
- Employees
- 10
- Website
- purple-biotech.com
- Address
- 4 Oppenheimer Street, Rehovot, TA, 7670104, IL
Purple Biotech (1YI0) Earnings & Revenues
1YI0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 3 | 2 |
| Technical Analysis | 2 | 1 | 0 |
| Moving Averages | 8 | 2 | 2 |













